BJDX Bluejay Diagnostics Inc Gross Profit Ratio

Corporate emblem and logo of Bluejay Diagnostics Inc (BJDX)

Bluejay Diagnostics (BJDX) gross trading margin demonstrates a dependency on FDA approval, as commercial inflow is currently blocked by the testing stage. High pricing power in the critical diagnostics segment and a bedside rapid sepsis analysis strategy support the company's potential. The value of 0.00 shows the latest value of this indicator, which determines production efficiency and the financial stability of the business.

Bluejay (BJDX) Return on Gross Profit: for the period 07/04/2022 - 11/19/2026

Financial and market metric breakdowns for Bluejay Diagnostics, Inc. (BJDX)

- stock value and consensus price forecast:
Fundamental valuation:BJDX - Bluejay Diagnostics, Inc.
Manufactured products of bluejaydx.com

The median gross margin on the GURU.Markets platform visualizes the efficiency of direct cost management, which is critical for assessing business scalability. This metric is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, measuring the portion of funds available to cover operating expenses. For Bluejay Diagnostics (BJDX), which is currently in the FDA stage, the absence of operating income makes this metric an indicator of future risks upon the launch of rapid tests.